News

JERUSALEM--(BUSINESS WIRE)--May. 14, 2013-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) will host a live audio webcast at the Bank of America Merrill Lynch 2013 Health Care Conference in Las Vegas, NV. Jon Congleton, Senior Vice President and General Manager, Global CNS will present on Wednesday, May 15, 2013. What:   Teva Presentation at the Bank of America Merrill Lynch 2013 Health Care Conference Read More »

Adasuve® (loxapine) inhalation powder is approved in the U.S. for the acute treatmentof agitation associated with schizophrenia and bipolar disorder NORTH WALES, Pa. & MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--May. 8, 2013-- Teva Pharmaceuticals USA, Inc., a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: TEVA), and Alexza Pharmaceuticals, Inc. (NASDAQ: ALXA) announced today that the companies have entered into an exclusive U.S. license and supply agreement for ADASUVE (loxapine) inhalation powder 10 mg for the acute Read More »

Click here for Webcast Net Revenues Total $4.9 Billion Non-GAAP Diluted EPS of $1.12; GAAP Diluted EPS of $0.74 Cash Flow from Operations of $1.1 Billion JERUSALEM--(BUSINESS WIRE)--May. 2, 2013-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) today reported results for the quarter ended March 31, 2013. “During the quarter, we were pleased by the overall performance of our specialty products and results of our OTC joint venture. Our generic operations, which are a core component of our business, performed in line with our expectations and were particularly strong in Western and East Read More »

-Plan B One-Step ® Will Soon Be Available in the Family Planning Aisle in Stores Across The Country- NORTH WALES, Pa.--(BUSINESS WIRE)--Apr. 30, 2013-- Teva Women’s Health, Inc., a U.S.-based subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), announced today that the U.S. Food and Drug Administration (FDA) has approved the emergency contraceptive Plan B One-Step® (levonorgestrel) tablet 1.5 mg for over-the-counter sale to consumers 15 years of age and older in the United States. This decision marks the continuation of improving access to emergency contraception for women and is t Read More »

JERUSALEM--(BUSINESS WIRE)--Apr. 29, 2013-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) today announced that Paul J. Sekhri has been appointed Group Executive Vice President, Global Business Development and Chief Strategy Officer. Mr. Sekhri has over 25 years of operational experience in the life sciences industry, including business development, business strategy, general management, drug development, and commercial strategy. In his new role, Mr. Sekhri will oversee Teva’s Strategy and Business Development group, reporting direc Read More »

Move is part of strategic plan to optimize commercialization Newly created group to utilize strong locally-led Generics presence to leverage Teva's globally-based Specialty offering Dr. Rob Koremans appointed President and CEO of Global Specialty Medicines Group JERUSALEM--(BUSINESS WIRE)--Apr. 24, 2013-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today the creation of a Global Specialty Medicines (GSM) group. Dr. Rob Koremans will serve as President and CEO Global Specialty Medicines. He will continue to serve on Teva’s Executive Committee and report to Dr. Jeremy Levin, Read More »

JERUSALEM & BURNABY, British Columbia--(BUSINESS WIRE)--Apr. 23, 2013-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and Xenon Pharmaceuticals Inc. (Xenon) announced today that the US Food and Drug Administration (FDA) has granted orphan-drug designation to the investigational drug XEN402 being developed for the treatment of pain associated with erythromelalgia (EM). EM is a rare autosomal dominant condition characterized by debilitating spontaneous or easily evoked attacks of symmetrical burning pain in the feet and hands, typically associated with elevated skin temperature and eryt Read More »

Data Reported Comparable Multiple Pregnancy Rates Among Patients Treated with Investigational Milprosa™ and Progesterone Vaginal Gel JERUSALEM--(BUSINESS WIRE)--Apr. 17, 2013-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) today presented data from a sub-analysis of a Phase III clinical trial of Milprosa™ (progesterone) vaginal ring, an investigational, once-weekly therapy for luteal phase support in women undergoing in vitro fertilization (IVF). The results were presented at the 61st Annual Meeting of the Pacific Coast Rep Read More »

JERUSALEM--(BUSINESS WIRE)--Apr. 9, 2013-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that it will release its first quarter 2013 financial results on Thursday, May 2, 2013 at 7:00 a.m. ET. Teva will host a conference call and live webcast on the same day, at 8:00 a.m. ET to discuss its first quarter 2013 results and overall business environment. A Question & Answer session will follow this discussion. In order to participate, please dial the following numbers (at least 10 minutes befor Read More »

Yoo Suk Hong, previous Lilly Korea CEO, recruited as first CEO of Teva-Handok Teva-Handok is scheduled to officially launch in September JERUSALEM & SEOUL, South Korea--(BUSINESS WIRE)--Apr. 8, 2013-- Teva-Handok today announced the appointment of Yoo Suk Hong as the first Chief Executive Officer of the business venture established between Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and Handok Pharmaceuticals (KRX: 002390). This business venture was formed in February, 2013 and fo Read More »